| Literature DB >> 31099820 |
Loïc Carment1,2, Lucile Dupin1,2, Laura Guedj3, Maxime Térémetz1,2, Marie-Odile Krebs1,2,3, Macarena Cuenca3,4,5, Marc A Maier2,5,6, Isabelle Amado1,2,3, Påvel G Lindberg1,2.
Abstract
Impairments in attentional, working memory and sensorimotor processing have been consistently reported in schizophrenia. However, the interaction between cognitive and sensorimotor impairments and the underlying neural mechanisms remains largely uncharted. We hypothesized that altered attentional processing in patients with schizophrenia, probed through saccadic inhibition, would partly explain impaired sensorimotor control and would be reflected as altered task-dependent modulation of cortical excitability and inhibition. Twenty-five stabilized patients with schizophrenia, 17 unaffected siblings and 25 healthy control subjects were recruited. Subjects performed visuomotor grip force-tracking alone (single-task condition) and with increased cognitive load (dual-task condition). In the dual-task condition, two types of trials were randomly presented: trials with visual distractors (requiring inhibition of saccades) or trials with addition of numbers (requiring saccades and addition). Both dual-task trial types required divided visual attention to the force-tracking target and to the distractor or number. Gaze was measured during force-tracking tasks, and task-dependent modulation of cortical excitability and inhibition were assessed using transcranial magnetic stimulation. In the single-task, patients with schizophrenia showed increased force-tracking error. In dual-task distraction trials, force-tracking error increased further in patients, but not in the other two groups. Patients inhibited fewer saccades to distractors, and the capacity to inhibit saccades explained group differences in force-tracking performance. Cortical excitability at rest was not different between groups and increased for all groups during single-task force-tracking, although, to a greater extent in patients (80%) compared to controls (40%). Compared to single-task force-tracking, the dual-task increased cortical excitability in control subjects, whereas patients showed decreased excitability. Again, the group differences in cortical excitability were no longer significant when failure to inhibit saccades was included as a covariate. Cortical inhibition was reduced in patients in all conditions, and only healthy controls increased inhibition in the dual-task. Siblings had similar force-tracking and gaze performance as controls but showed altered task-related modulation of cortical excitability and inhibition in dual-task conditions. In patients, neuropsychological scores of attention correlated with visuomotor performance and with task-dependant modulation of cortical excitability. Disorganization symptoms were greatest in patients with weakest task-dependent modulation of cortical excitability. This study provides insights into neurobiological mechanisms of impaired sensorimotor control in schizophrenia showing that deficient divided visual attention contributes to impaired visuomotor performance and is reflected in impaired modulation of cortical excitability and inhibition. In siblings, altered modulation of cortical excitability and inhibition is consistent with a genetic risk for cortical abnormality.Entities:
Keywords: attention; cortical excitability; eye movement; force control; schizophrenia
Mesh:
Year: 2019 PMID: 31099820 PMCID: PMC6598624 DOI: 10.1093/brain/awz127
Source DB: PubMed Journal: Brain ISSN: 0006-8950 Impact factor: 13.501
Clinical and demographic data
| PSZ ID | Age, y | Gender | Disease AAO | CPZ, mg/day | PANSS | BPRS (24–168) | SAS (0–44) | AIMS (0–40) | Neurological soft signs | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total score (30–210) | Positive symptoms (7–49) | Negative symptoms (7–49) | General symptoms (16–112) | Disorganization symptoms (4–28) | Total score (0–105) | Sensory integration subscore (0–15) | Motor coordination subscore (0–21) | Motor integration subscore (0–18) | ||||||||
| 1 | 21 | F | 15 | 80 | 63 | 10 | 15 | 38 | 7 | 48 | 0 | 2 | 1.5 | 0 | 0.5 | 0 |
| 2 | 25 | M | 21 | 35 | 54 | 13 | 11 | 30 | 10 | 46 | 4 | 0 | 18.5 | 0.5 | 9 | 2 |
| 3 | 32 | F | 27 | 200 | 52 | 7 | 18 | 27 | 9 | 32 | 2 | 0 | 22 | 1.5 | 12.5 | 5 |
| 4 | 44 | M | 23 | 200 | 63 | 12 | 16 | 35 | 7 | 52 | 3 | 0 | 12.5 | 0.5 | 6.5 | 0 |
| 5 | 28 | M | 22 | 250 | 50 | 9 | 14 | 27 | 11 | 36 | 4 | 3 | 18.5 | 1 | 9.5 | 1 |
| 6 | 22 | M | 12 | 200 | 56 | 9 | 14 | 33 | 12 | 40 | 1 | 0 | 13 | 4.5 | 5.5 | 2 |
| 7 | 24 | M | 17 | 800 | 64 | 14 | 16 | 34 | 4 | 44 | 6 | 5 | 16.5 | 0 | 5.5 | 2.5 |
| 8 | 38 | M | 20 | 300 | 44 | 9 | 12 | 23 | 6 | 37 | 2 | 2 | 6 | 0.5 | 3.5 | 0 |
| 9 | 31 | F | 30 | 267 | 50 | 13 | 17 | 20 | 7 | 44 | 5 | 1 | 18.5 | 3.5 | 7 | 1 |
| 10 | 29 | M | 23 | 75 | 44 | 9 | 9 | 26 | 6 | 36 | 2 | 0 | 5.5 | 0 | 3.5 | 0 |
| 11 | 36 | M | 29 | 200 | 52 | 10 | 13 | 29 | 4 | 44 | 1 | 1 | 9 | 1 | 7 | 0 |
| 12 | 49 | F | 42 | 150 | 63 | 16 | 14 | 33 | 7 | 46 | 2 | 0 | 11.5 | 1.5 | 3 | 1 |
| 13 | 32 | M | 31 | 200 | 63 | 9 | 21 | 33 | 6 | 45 | 1 | 0 | 7.5 | 1 | 4 | 1 |
| 14 | 38 | F | 32 | 200 | 56 | 9 | 11 | 36 | 9 | 41 | 6 | 0 | 18 | 0.5 | 7.5 | 1.5 |
| 15 | 18 | F | 15 | 100 | 59 | 13 | 16 | 30 | 12 | 40 | 2 | 1 | 11.5 | 2 | 5 | 1 |
| 16 | 42 | M | 16 | 300 | 81 | 14 | 28 | 39 | 11 | 49 | 6 | 3 | 19.5 | 2 | 7.5 | 3 |
| 17 | 18 | M | 15 | 300 | 51 | 14 | 13 | 24 | 11 | 42 | 3 | 3 | 21 | 5.5 | 6 | 4 |
| 18 | 29 | M | 24 | 200 | 44 | 7 | 11 | 26 | 7 | 36 | 8 | 0 | 16.5 | 1 | 7 | 0 |
| 19 | 39 | M | 19 | 300 | 47 | 10 | 11 | 26 | 10 | 40 | 1 | 0 | 17.5 | 4 | 8 | 1 |
| 20 | 30 | M | 23 | 100 | 54 | 8 | 10 | 36 | 4 | 46 | 0 | 0 | 3 | 0 | 3 | 0 |
| 21 | 24 | M | 20 | 1067 | 61 | 10 | 17 | 34 | 9 | 48 | 2 | 1 | 14.5 | 2.5 | 5.5 | 2 |
| 22 | 25 | M | 25 | 67 | 52 | 10 | 19 | 23 | 4 | 44 | 13 | 7 | 21 | 4 | 1.5 | 1 |
| 23 | 32 | M | 21 | 267 | 64 | 14 | 14 | 36 | 8 | 64 | 1 | 0 | 13.5 | 2 | 4 | 0.5 |
| 24 | 20 | F | 19 | 250 | 57 | 9 | 21 | 27 | 9 | 45 | 3 | 0 | 11.5 | 4 | 3.5 | 0 |
| 25 | 44 | M | 23 | 1067 | 59 | 10 | 12 | 37 | 9 | 38 | 0 | 0 | 16 | 2 | 8.5 | 1.5 |
| PSZ, mean ± SD | 31 ± 9 | 7F 18M | 23 ± 7 | 287 ± 276 | 56 ± 8 | 11 ± 8 | 15 ± 4 | 31 ± 5 | 8 ± 3 | 43 ± 7 | 3.1 ± 2.9 | 1.2 ± 1.8 | 13.8 ± 5.8 | 1.8 ± 1.6 | 5.8 ± 2.7 | 1.2 ± 1.3 |
| HC, mean ± SD | 30 ± 7 | 7F 18M | - | - | - | - | - | - | - | - | 1.3 ± 1.1* | 0.3 ± 0.4 | 7.6 ± 3.5*** | 0.9 ± 1.1* | 3.8 ± 2.1** | 0.5 ± 0.7* |
| SIB, mean ± SD | 35 ± 10 | 12F 5M | - | - | - | - | - | - | - | - | 1.1 ± 1.3* | 0 ± 0* | 7.3 ± 3.8*** | 0.8 ± 0.8* | 3.8 ± 2.7* | 0.8 ± 0.7 |
Detailed clinical data for patients with schizophrenia. Disease onset relates to first hospital assignment including diagnosis. Patients were assessed for with the PANSS, brief psychiatric rating scale (BPRS), Simpson Angus Extra-Pyramidal Scale (SAS), Abnormal Involuntary Movements Scale (AIMS), and neurological soft signs. There was no difference in the demographic data between groups. Group differences for clinical data tested with Mann-Whitney U-tests are displayed as follow: *P < 0.05; **P < 0.01, ***P < 0.001. Patient 22 was identified as an outlier in SAS score, but not in other scores (behavioural or neurophysiological measures) and this did not affect group results (see Supplementary material for detailed analysis).
AAO = age at onset; CPZ = chlorpromazine; F = female; HC = healthy control group; M = male; PSZ = patients with schizophrenia; SIB = non-psychotic siblings.
Figure 1Visuomotor grip force-tracking set-up and conditions. Set-up for the visuomotor task: subjects were seated in front of a 22” computer screen, set at eye level at a distance of 60 cm with head stabilized (forehead and chin rest). The screen displayed the visuomotor force-tracking tasks. Grip force was displayed as a red cursor moving vertically and in real-time as a function of the exerted grip force. The target force was displayed as a right-to-left scrolling coloured line. A trial consisted of a single ramp-hold-and-release sequence. Trials with different cognitive load were presented pseudo-randomly: (i) single-task trial (Single): grip force-tracking; (ii) dual-task distraction trial (Dual-DIST): during force-tracking, distractors, consisting of white-filled shapes (square, star, triangle, 2 × 2 cm), were randomly displayed for 500 ms in the four periods at specific times (1500 ms into Rest; 380 ms before Ramp onset; 1500 ms into Hold; and 380 ms before Release); (iii) dual-task addition trial (Dual-ADD): while subjects performed the force-tracking task, numbers (from 1 to 9, 2 × 2 cm) were displayed for 500 ms with onset times identical to the Dual-DIST trials. Subjects were instructed to focus on the tracking task and to inhibit saccades toward irrelevant visual stimuli (distractors), but to make saccades toward relevant stimuli (numbers). They were asked to mentally sum the successive numbers, and report the sum when given a cue.
Figure 4Cortical excitability. (A) Raw data of MEPs recorded during the visuomotor grip force-tracking task (hold period) for a patient with schizophrenia (PSZ) and a healthy control subject (HC). Example trials show an unconditioned MEP (dark line) and a conditioned MEP (grey line) of the 1DI for (i) the single-task force-tracking condition (Single) and the dual-task condition with (ii) dual-task distraction trial (Dual-DIST) and (iii) dual-task addition trial (Dual-ADD). (B) Mean normalized amplitude of MEPs for the hold period (estimated marginal mean ± vertical bars: 95% CI) during Single (grey), Dual-DIST (pink) and Dual-ADD (cyan) trials for the three groups: patients with schizophrenia, healthy controls and siblings (SIB). Triangles represent data points of the individual subjects in each group and condition. Significant differences (LSD fisher post hoc tests for between-group comparisons are shown as horizontal black brackets and within-group comparisons as horizontal grey dashed bracket with: *P < 0.05; **P < 0.01, ***P < 0.001. For clarity, significant differences for between-group comparisons are only indicated between patients and healthy controls. Post hoc tests for between-group comparisons (not indicated) revealed that patients with schizophrenia showed an increased excitability only in single-task condition compared to healthy controls (patients with schizophrenia versus healthy controls: P = 0.02), this was not significantly different compared to siblings (patients with schizophrenia versus siblings: P = 0.08).
Visuomotor measures for the three groups
| Visuomotor measures | Patients with schizophrenia, Mean ± SD | Healthy control subjects Mean ± SD | Non-psychotic siblings Mean ± SD | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Single task | Dual-DIST | Dual-ADD | Single task | Dual DIST | Dual ADD | Single task | Dual-IST | Dual-ADD | |
|
| |||||||||
| Tracking error, RMSe | 0.12 ± 0.05 | 0.15 ± 0.07 | 0.17 ± 0.09 | 0.09 ± 0.03 | 0.10 ± 0.04 | 0.12 ± 0.04 | 0.09 ± 0.03 | 0.11 ± 0.03 | 0.13 ± 0.04 |
| Release duration, ms | 166 ± 46 | 171 ± 61 | 179 ± 89 | 148 ± 30 | 142 ± 45 | 145 ± 44 | 140 ± 33 | 135 ± 53 | 136 ± 54 |
| Force-onset, ms | 118 ± 22 | 119 ± 38 | 150 ± 120 | 115 ± 29 | 120 ± 46 | 132 ± 50 | 113 ± 35 | 105 ± 22 | 113 ± 22 |
| Force-offset, ms | 165 ± 50 | 166 ± 62 | 171 ± 59 | 161 ± 43 | 155 ± 47 | 160 ± 46 | 151 ± 33 | 136 ± 41 | 157 ± 39 |
|
| |||||||||
| Saccade detection, % | 58 ± 24 | 34 ± 24 | 70 ± 23 | 36 ± 16 | 14 ± 9 | 74 ± 19 | 38 ± 21 | 17 ± 14 | 69 ± 20 |
| Saccade latency, ms | X | 217 ± 53 | 321 ± 65 | X | 182 ± 30 | 378 ± 72 | X | 180 ± 27 | 354 ± 68 |
| Saccade duration, ms | X | 161 ± 89 | 232 ± 71 | X | 157 ± 77 | 189 ± 50 | X | 117 ± 75 | 192 ± 57 |
| SPEM gain, ratio | 0.60 ± 0.34 | X | X | 0.86 ± 0.25 | X | X | 0.89 ± 0.22 | X | X |
|
| |||||||||
| MEPs, NU | 1.83 ± 0.54 | 1.70 ± 0.51 | 1.74 ± 0.55 | 1.43 ± 0.37 | 1.53 ± 0.46 | 1.60 ± 0.51 | 1.51 ± 0.54 | 1.56 ± 0.56 | 1.53 ± 0.51 |
| SICI, % | 30 ± 15 | 28 ± 13 | 29 ± 14 | 38 ± 14 | 44 ± 13 | 43 ± 14 | 39 ± 15 | 42 ± 20 | 43 ± 18 |
| CSP, ms | 745 ± 164 | 773 ± 122 | 810 ± 166 | 906 ± 177 | 887 ± 167 | 917 ± 174 | 848 ± 201 | 812 ± 188 | 793 ± 204 |
Main measures (mean ± SD) of performance in force control, eye tracking and TMS are detailed for all groups in (i) the Single-task tracking condition and the two Dual-task conditions with (ii) dual-task distraction trials (Dual-DIST) and (iii) dual-task addition trials (Dual-ADD).
Note that saccade occurrence in Dual-ADD did not reach 100% since subjects tended to avoid saccades to targets with small eccentricity (relative to the cursor). Saccade detection in the single-task condition is the occurrence of spontaneous non-required but task-related saccades during grip force-tracking (patients with schizophrenia versus healthy control subjects: P < 0.001; patients with schizophrenia versus non-psychotic siblings: P = 0.01).
CSP = cortical silent period; HC = healthy control group; NU = normalized unit (normalized on Rest values); PSZ = patients with schizophrenia; RMSe = root mean square error; SIB = non-psychotic siblings; X = absence of data in this condition.
Figure 2Force control accuracy. (A) Raw data of single trials of grip force-tracking for a patient with schizophrenia (PSZ) and a healthy control subject (HC) for (i) the single-task force-tracking condition (Single) and the dual-task condition with (ii) dual-task distraction trial (Dual-DIST) and (iii) dual-task addition trial (Dual-ADD). Exerted force = solid line; target force (ramp-hold-and-release profile) = dotted grey line. Although the patient with schizophrenia seemed to perform the force matching task with less accuracy, the task was achieved; the overall modulation of force follows the target force throughout the trial, the force modulation is neither flat nor random, and the target hold-force level was reached (see Supplementary material for detailed analysis). (B) Mean RMS tracking-error (estimated marginal mean ± vertical bars: 95% confidence interval, CI) during Single (grey), Dual-DIST (pink) and Dual-ADD trials (cyan) for the three groups: patients with schizophrenia, healthy controls and siblings (SIB). Triangles represent data points of the individual subjects in each group and condition. Significant differences (LSD fisher post hoc tests for between group comparisons are shown as horizontal black brackets and within group comparisons as horizontal grey dashed brackets with: *P < 0.05; **P < 0.01, ***P < 0.001. For clarity, significant differences for between-group comparisons are only indicated between patients and healthy controls. Post hoc tests for between-group comparisons revealed that patients had increased error in the three conditions compared to controls (patients with schizophrenia versus healthy controls, Single: P = 0.03; Dual-DIST: P = 0.001; Dual-ADD: P < 0.001), but also to siblings (patients with schizophrenia versus siblings, Single: P = 0.04; DIST: P = 0.002; Dual-ADD: P < 0.001). Post hoc tests for within group comparisons revealed that DIST condition led to increased error compared to Single-task condition only in the patients with schizophrenia group (patient with schizophrenia: P = 0.003; healthy controls: P = 0.24; siblings: P = 0.88). However, Dual-ADD trials led to increased error compared to Single-task trials in all groups (patient with schizophrenia: P < 0.001; healthy controls: P < 0.001; siblings: P < 0.001).
Figure 3Saccadic execution. (A) Raw data of vertical eye position recorded during the visuomotor grip force-tracking task for a patient with schizophrenia (PSZ) and a healthy control subject (HC). Example trials show saccades (solid line) relative to the appearance of a visual stimulus (dotted grey line) during the dual-task condition: (i) dual-task distraction trial (Dual-DIST) where subjects had to inhibit saccades toward visual distractors; and (ii) dual-task addition trial (Dual-ADD) where subjects had to exert a saccade toward the stimulus (number). Initial gaze position corresponds to the vertical cursor (force-tracking) position; maximal gaze amplitude corresponds to vertical position of the number or distractor. (B) Mean percentage of exerted saccades toward visual stimuli (estimated marginal mean ± vertical bars: 95% CI) during Dual-DIST (displayed in pink) and Dual-ADD trials (displayed in cyan) for the three groups: patients with schizophrenia, healthy controls and siblings (SIB). Triangles represent data points of the individual subjects in each group and condition. Significant differences (LSD fisher post hoc tests for between group comparisons are shown as horizontal black brackets and within group comparisons as horizontal grey dashed brackets with: *P < 0.05; **P < 0.01, ***P < 0.001. For clarity, significant differences for between-group comparisons are only indicated between patients and healthy controls.
Neurophysiological data: non task-related baseline assessment for the three groups
| Neurophysiological assessments | Patients with schizophrenia Mean ± SD | Healthy control subjects Mean ± SD | Non-psychotic siblings Mean ± SD |
|---|---|---|---|
|
| |||
| Right hand, N | 384 ± 113 | 411 ± 124 | 326 ± 73 |
| Left hand, N | 346 ± 104 | 398 ± 112 | 334 ± 84 |
|
| |||
| Resting motor threshold, % stimulator | 54 ± 11 | 52 ± 8 | 50 ± 9 |
| Unconditioned MEP amplitude, mV | 1.80 ± 1.06 | 1.70 ± 0.98 | 1.98 ± 1.44 |
| Conditioned MEP amplitude, mV | 0.85 ± 0.53 |
|
|
| SICI, % reduction | 53 ± 17 |
|
|
|
| |||
| REST EMG activity (mV) | 0.004 ± 0.003 | 0.003 ± 0.002 | 0.004 ± 0.002 |
| HOLD EMG activity (mV) | 0.018 ± 0.007 | 0.017 ± 0.010 | 0.016 ± 0.008 |
MVC for each hand was tested using force dynamometer. Resting motor threshold, MEPs for unconditioned and conditioned stimulus and SICI were obtained at baseline. Control elements were obtained 1500 ms prior to the stimulation during the rest and hold phases of the visuomotor tracking task. This to show that any changes in MEP amplitude cannot be attributed to group differences in EMG background activity. Group differences (t-tests) are displayed as follow: *P < 0.05; **P < 0.01, ***P < 0.001.
Figure 5Modulation of cortical excitability and inhibition, relation to clinical score (PANSS). (A) Strength of modulation of cortical excitability (CE Modulation) for dual-task addition (Dual-ADD) compared to single-task trials (Single). This delta score (MEPDual-ADD − MEPSingle) corresponds to the mean MEP amplitude in Dual-ADD minus that in Single (estimated marginal mean ± vertical bars: 95% CI). For patients with schizophrenia (PSZ, grey), healthy control subjects (HC, dark grey) and siblings (SIB, white). Triangles represent data points of the individual subjects in each group. Significant differences between groups (LSD fisher post hoc tests) shown as horizontal brackets with: *P < 0.05, ***P < 0.001. (B) Strength of SICI modulation (CI Modulation); as in A but for (SICIDual-ADD − SICISingle). (C) Spearman’s correlation between delta score of cortical excitability (CE-M) and symptom severity: PANSS disorganization subscore for patients with schizophrenia (r = − 0.69, P = 0.001).